DistributionEquity
$RVPH
From the Lytham Partners presentation
Upcoming Timeline
Q4 2026: FDA feedback on the new formulation/bridging strategy
Q4 2026 /Q1 2027: Bridging/bioavailability study
Q4 2026 / Q1 2027: Patent grant on the improved formulation
H1 2027: Planned start of RECOVER-2
H1 2027: Targeted Nasdaq uplisting
Mid-2028: Expected RECOVER-2 topline data
Late 2028 / Q1 2029: Planned NDA filing
Late 2029: Potential FDA approval
1
2